We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.22 | -0.15% | 149.70 | 149.89 | 147.82 | 149.89 | 6,532,721 | 00:38:06 |
By Chris Wack
Johnson & Johnson said Friday that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center to support the development of a preventive vaccine candidate for Covid-19.
The companies have begun preclinical testing of multiple vaccine prospects, with an aim to identify by the end of March a Covid-19 vaccine candidate for clinical trials.
Janssen said it is optimistic that, in collaboration with multiple global strategic partners, it can initiate a Phase 1 clinical study of a potential vaccine candidate by the end of the year. Janssen is preparing to upscale production and manufacturing capacities to levels required to meet global public health vaccination needs.
Janssen said it is using its proven vaccine technology used to develop investigational Ebola, Zika, RSV and HIV vaccines. Research and collaboration on preclinical work for Zika and HIV vaccine candidates at the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center was foundational to developing these vaccines.
Janssen said it is also working closely with global strategic partners to screen its library of antiviral molecules to accelerate the discovery of potential Covid-19 treatments.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 13, 2020 10:15 ET (14:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions